← Back to Search

CAR T-cell Therapy

BMS-986393 for Multiple Myeloma (QUINTESSENTIAL Trial)

Phase 2

Recruiting

Research Sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to approximately 5 years

Awards & highlights

QUINTESSENTIAL Trial Summary

This trial aims to test how well BMS-986393 works and how safe it is for people with multiple myeloma that has come back or not responded to previous treatment.

Who is the study for?

This trial is for adults with multiple myeloma that has come back or hasn't responded to treatment. Specific details about who can join are not provided, but typically participants need to meet certain health standards and have a history of the condition being studied.Check my eligibility

What is being tested?

The study is testing BMS-986393, which is a CAR T cell therapy targeting GPRC5D, a protein often found on myeloma cells. The goal is to see how effective and safe this therapy is in treating patients whose multiple myeloma has relapsed or resisted other treatments.See study design

What are the potential side effects?

While specific side effects for BMS-986393 aren't listed here, common ones for CAR T cell therapies include flu-like symptoms, fatigue, fever, difficulty breathing, and changes in blood pressure. Some may experience more severe immune reactions.

QUINTESSENTIAL Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to approximately 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to approximately 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Secondary outcome measures

Area under the concentration-time curve (AUC)

BOR of complete response (CR) [including stringent complete response sCR]

BOR of partial response (PR) or better

+20 more

QUINTESSENTIAL Trial Design

1Treatment groups

Experimental Treatment

Group I: BMS-986393Experimental Treatment1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyLead Sponsor

14 Previous Clinical Trials

1,577 Total Patients Enrolled

5 Trials studying Multiple Myeloma

308 Patients Enrolled for Multiple Myeloma

Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb

1,508 Previous Clinical Trials

3,370,273 Total Patients Enrolled

72 Trials studying Multiple Myeloma

25,137 Patients Enrolled for Multiple Myeloma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

In how many distinct locations is this investigation currently being conducted?

"A total of 25 sites are currently active for patient enrollment in this trial, including but not limited to the University of Kansas Medical Center in Kansas City, Roswell Park Cancer Institute in Buffalo, and Moffitt Cancer Center in Tampa."

Answered by AI

Are there ongoing efforts to actively enroll participants for this clinical trial?

"As per clinicaltrials.gov, this investigation is not presently seeking participants. This study was first listed on April 15th, 2024 and last revised on February 28th, 2024. Despite the current lack of patient recruitment for this trial, there are currently 807 other studies actively seeking eligible individuals to participate."

Answered by AI

Has the drug BMS-986393 received approval from the FDA?

"Based on the current phase of this trial, our team at Power rates BMS-986393 with a safety score of 2. This reflects available safety data but lacks evidence regarding efficacy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

2024. "Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06297226.

All > Pflugerville Tx > Greensboro